<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02394600</url>
  </required_header>
  <id_info>
    <org_study_id>EEU-MERCK 001</org_study_id>
    <nct_id>NCT02394600</nct_id>
  </id_info>
  <brief_title>The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis - a Pilot Evaluation</brief_title>
  <official_title>The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis - a Pilot Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is a Phase IV, single center, placebo-controlled, parallel study design
      conducted using the Environmental Exposure Unit (EEU). The study will aim to be determine
      whether there are any benefits from Grastek® for the treatment of birch-pollen induced
      allergic rhinoconjunctivitis. Grastek® is a Health Canada and FDA approved sublingual
      immunotherapy (SLIT) for the treatment of grass-pollen induced allergic rhinoconjunctivitis.
      The EEU provides a closed environment in which participants are exposed to a predetermined,
      controlled, constant level of airborne pollen. 96 participants will complete this study and
      will either receive Grastek® or placebo in a 1:1 ratio. The study will consist of a screening
      visit, a pre-treatment pollen exposure visit, 60 days of treatment with Grastek® or placebo,
      two treatment visits and a follow-up pollen exposure visit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Nasal Symptom Score (TNSS) From Baseline to Post-treatment.</measure>
    <time_frame>4 months</time_frame>
    <description>To determine the effect of 4 months of treatment with Grastek® on the symptoms of birch pollen induced AR in participants with both timothy grass pollen-induced and birch pollen-induced allergen rhinitis (AR)
TNSS is comprised of the sum of 4 symptoms: runny nose, itchy nose sneezing and nasal congestion. Each of these symptoms are evaluated based on a 4 point Likert scale from 0-3. 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms. TNSS can therefore have a range from 0 to 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of Blood Samples for Potential Biomarkers by Comparing Baseline and Post-treatment Samples.</measure>
    <time_frame>4 months</time_frame>
    <description>To determine potential biomarkers predictive of clinical efficacy for birch pollen-induced AR following treatment with Grastek®</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Allergic Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Grastek®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>48 participants will receive Grastek® once per day for 120 days. Grastek® is a standardized sublingual immunotherapy (SLIT) tablet containing 2800 BAU of standardized allergen extract from Timothy grass (Phleum pretense). This SLIT product is approved by Health Canada and the Food and Drug Administration (FDA) for the treatment of grass-pollen induced allergic rhinoconjunctivitis (AR) in Canada and the United States respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>48 participants will receive placebo once per day for 120 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grastek®</intervention_name>
    <description>one tablet daily for four months</description>
    <arm_group_label>Grastek®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one tablet daily for four months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant demonstrates understanding and has provided an appropriately signed and
             dated informed consent.

          2. Male or Female, 18 to 65 years of age, at time of the Screening visit.

          3. Participant has a history of at least moderate allergic rhinoconjunctivitis due to
             hypersensitivity to birch pollen for a minimum of 2 years.

          4. Participant responds to the birch pollen and timothy grass pollen through a standard
             skin prick test administered at the Screening visit. A positive test will be defined
             as a wheal diameter at least 5mm or larger than the negative control (normal saline)
             wheal. A historical skin-prick test performed within three-hundred sixty-five (365)
             days or one (1) year at the site will be accepted in lieu of performing a new skin
             prick test.

          5. Participant understands and is willing, able and likely to comply with study
             procedures and restrictions.

          6. Participant, if female, has a negative urine pregnancy test at Visit 1 and is willing
             to use a medically acceptable form of birth control. Acceptable methods of birth
             control for this study include:

               -  oral, patch, or intra-vaginal hormonal contraceptives

               -  Norplant System®

               -  Depo-Provera®

               -  IUD

               -  double barrier method

               -  abstinence

               -  surgically sterile females (hysterectomy or tubal ligation)

               -  &gt; 1 year post-menopausal females

               -  same sex partner

               -  partner vasectomy (&gt; 3 months)

          7. Participant is healthy as determined by pre-study medical history, physical
             examination and vital signs.

          8. Participant is able to read, comprehend, and record all information in English.

          9. Participant has a serum specific IgE level to both birch and timothy grass of ≥0.7
             ku/L.

        Exclusion Criteria:

          1. Has significant current nasal or ocular symptoms that the study doctor associates with
             perennial allergic or non-allergic rhinitis.

          2. Female participant who is pregnant or lactating.

          3. Has a history of any illness that, in the opinion of the study investigator, might
             confound the results of the study or poses an additional risk to the participant by
             their participation in the study. This includes a clinically relevant medical or
             surgical history or presence of other respiratory disease (exceptions made for asthma
             and allergic rhinitis as defined in further exclusion criteria), or gastrointestinal,
             renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric,
             musculoskeletal, immunological, dermatological, connective tissue diseases or
             disorders, or a history of malignancy within the past 5 years, with the exception of
             non-melanoma skin cancer.

          4. Has any significant abnormalities found during physical exam as determined by the
             investigator.

          5. Has a current medical history of significant pulmonary disease and/or active asthma
             requiring daily drug therapy. Mild, intermittent asthma is permitted (managed with
             short acting beta-agonist less than 3 times per week). Isolated exercise-induced
             bronchospasm is also permitted.

          6. Has received an investigational drug within the last thirty (30) days.

          7. Has had use of immunotherapy containing grass or birch within the last 3 years.

          8. Has significant nasal polyps, nasal septal perforation, or nasal tract malformations
             as noted on physical exam.

          9. Administration of adrenaline (epinephrine) is contraindicated (e.g. participants with
             acute or chronic symptomatic coronary heart disease or concomitant beta-blocker
             therapy).

         10. Is unlikely to cooperate with the requirements of the study including having the
             ability to communicate with the investigator appropriately.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne K Ellis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <results_first_submitted>December 12, 2016</results_first_submitted>
  <results_first_submitted_qc>June 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2018</results_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. Anne Ellis</investigator_full_name>
    <investigator_title>Chair, Division of Allergy &amp; Immunology</investigator_title>
  </responsible_party>
  <keyword>rhinitis</keyword>
  <keyword>allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Grastek</title>
          <description>4 months of once per day Grastek sublingual immunotherapy</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>4 months of once per day matching placebo sublingual tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Grastek</title>
          <description>4 months of once per day Grastek sublingual immunotherapy</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>4 months of once per day matching placebo sublingual tablet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="93"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.89" lower_limit="18" upper_limit="65"/>
                    <measurement group_id="B2" value="38.17" lower_limit="22" upper_limit="58.75"/>
                    <measurement group_id="B3" value="38.03" lower_limit="18" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Nasal Symptom Score (TNSS) From Baseline to Post-treatment.</title>
        <description>To determine the effect of 4 months of treatment with Grastek® on the symptoms of birch pollen induced AR in participants with both timothy grass pollen-induced and birch pollen-induced allergen rhinitis (AR)
TNSS is comprised of the sum of 4 symptoms: runny nose, itchy nose sneezing and nasal congestion. Each of these symptoms are evaluated based on a 4 point Likert scale from 0-3. 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms. TNSS can therefore have a range from 0 to 12.</description>
        <time_frame>4 months</time_frame>
        <population>93 participants were randomized into this study. The final number of participants that completed and were included for analysis are listed above.</population>
        <group_list>
          <group group_id="O1">
            <title>Grastek</title>
            <description>4 months of once per day Grastek sublingual immunotherapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>4 months of once per matching placebo sublingual tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Nasal Symptom Score (TNSS) From Baseline to Post-treatment.</title>
          <description>To determine the effect of 4 months of treatment with Grastek® on the symptoms of birch pollen induced AR in participants with both timothy grass pollen-induced and birch pollen-induced allergen rhinitis (AR)
TNSS is comprised of the sum of 4 symptoms: runny nose, itchy nose sneezing and nasal congestion. Each of these symptoms are evaluated based on a 4 point Likert scale from 0-3. 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms. TNSS can therefore have a range from 0 to 12.</description>
          <population>93 participants were randomized into this study. The final number of participants that completed and were included for analysis are listed above.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.5" upper_limit="3.1"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1.4" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of Blood Samples for Potential Biomarkers by Comparing Baseline and Post-treatment Samples.</title>
        <description>To determine potential biomarkers predictive of clinical efficacy for birch pollen-induced AR following treatment with Grastek®</description>
        <time_frame>4 months</time_frame>
        <population>As the primary outcome showed that there was no significant difference between Grastek and placebo this outcome was not able to be completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Grastek</title>
            <description>4 months of once per day Grastek sublingual immunotherapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>4 months of once per matching placebo sublingual tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Blood Samples for Potential Biomarkers by Comparing Baseline and Post-treatment Samples.</title>
          <description>To determine potential biomarkers predictive of clinical efficacy for birch pollen-induced AR following treatment with Grastek®</description>
          <population>As the primary outcome showed that there was no significant difference between Grastek and placebo this outcome was not able to be completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Grastek®</title>
          <description>4 months of once per day Grastek sublingual immunotherapy</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>4 months of once per day matching placebo sublingual tablet</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Palate pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Sublingual pruritus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Throat pruritus</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Tongue pruritus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Anne Ellis</name_or_title>
      <organization>Kingston General Hospital</organization>
      <phone>613-548-2336</phone>
      <email>ellisa@kgh.kari.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

